Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vismodegib for Steroid-Refractory Sclerodermatous Chronic GVHD
NCT02337517Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Sep 2015
- Primary completion
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of vismodegib in chronic graft-versus-host disease (cGVHD), sponsored by National Cancer Institute. Started Sep 2015; status: terminated.
02
Drugs
vismodegib
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on NCT02337517.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02337517.